Previous
Poster Home
Next
A Phase I Study of TAS102 Plus Talazoparib in Advanced Colorectal (CRC) and Esophagogastric (EGC) Adenocarcinomas.
07:30am - 03:35pm EST - April 5, 2024
Information
Resources
Abstract: JNCCN23-0513
https://jnccn.org/view/journal...
Author(s):
Christos Fountzilas, MD
, Roswell Park Comprehensive Cancer Center
Tags:
Member Institution
NCCN Foundation Young Investigator Award
Clinical Oncology
Display Label
Action
TAS102 PARPi NCCN 2024 poster.pdf
Download Handout